Paper Details

  1. Home
  2. Paper Details

Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults.

Author: BidadiK, GourlayS, HayesJ, ShresthaM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Continuous nebulized albuterol treatment, at either high or standard doses, was found to be more effective in improving FEV1 in patients with acute asthma compared to intermittent treatment. The standard-dose continuous-treatment regimen had the greatest improvement in FEV1 with the least number of side effects.
Paper Details　
Original Abstract of the Article :
Adult patients suffering from acute asthma presenting to the Emergency Department with an FEV1 of less than 40% of predicted were randomized into four treatment groups. They were treated with nebulized albuterol at a high (7.5 mg) or standard (2.5 mg) dose given either continuously through 1 h, or i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1378/chest.110.1.42

データ提供：米国国立医学図書館（NLM）

Severe Acute Asthma: Finding a Path Through the Desert of Airway Obstruction

Severe acute asthma can feel like navigating a vast desert of airway obstruction, making breathing a struggle. This research explores the effectiveness of continuous versus intermittent albuterol, at high and low doses, in treating severe acute asthma in adults. The study employed a randomized controlled trial to compare the efficacy of different albuterol administration strategies in adult patients with severe asthma.

Albuterol: Finding the Right Oasis for Airway Relief

The study revealed that continuous nebulized albuterol, administered at both high and standard doses, provided the greatest improvement in lung function compared to intermittent albuterol. The researchers found that continuous albuterol, like a constant source of hydration in a desert, provided more effective relief from airway obstruction. This research suggests that continuous albuterol administration may be a more effective strategy for managing severe acute asthma.

Navigating the Desert of Asthma

This research highlights the importance of finding the right treatment strategy for managing severe acute asthma, like finding a reliable oasis in the desert. It emphasizes the need for close collaboration with healthcare professionals to determine the most effective treatment approach for individual patients. By working together, individuals can find a more manageable path through the desert of asthma and improve their quality of life.

Dr.Camel's Conclusion

The desert of severe acute asthma can be a terrifying and debilitating experience, but continuous albuterol administration offers a glimmer of hope, like a refreshing oasis in the sand. This research highlights the potential of this treatment strategy for providing effective relief from airway obstruction. It emphasizes the importance of working closely with healthcare professionals to find the most effective path through the desert of asthma and achieve better overall health outcomes.

Date :
  1. Date Completed 1996-08-21
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

8681661

DOI: Digital Object Identifier

10.1378/chest.110.1.42

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.